Our mission is to develop radiopharmaceutical therapies that result in improved patient outcomes by delivering high radiation doses to tumours, without compromising on normal organ safety.
Founded in 2021 as a subsidiary of Bracco Imaging, the company was then partly spun out with Series A financing in 2024. Blue Earth Therapeutics unites a UK/US-based team with deep expertise across radiopharmaceutical development, oncology, and operations. Our leadership has proven track records in bringing innovative radiopharmaceuticals from concept to clinic.
With a strong foundation of proven leadership, scientific innovation, and strategic partnerships, Blue Earth Therapeutics is shaping the future of precision radiopharmaceutical therapies. Our initial focus is on prostate cancer, where we are advancing a pipeline of PSMA-targeted radiohybrid assets. Blue Earth Therapeutics operates through a reliable supply chain, leveraging a trusted network of external partners to ensure consistent manufacturing and global access while maintaining operational agility.
Contact Us
Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford
OX4 4GA, UK
